semaglutide cardiac effects in Cardiometabolic Diseases: SELECTing the Target Population People think I'm crazy when

Keep Zepbound on Formulary

Based on clinical trial data for GLP-1 weight loss, tirzepatide (Zepbound) produces the highest average at approximately 2022.5% of body weight

Supplementation using NO precursors such as L-arginine and beetroot extracts, as well as LC, resulted in a significant increase in circulating 25(OH)VD levels and a decrease in oxidative stress and inflammation [147]

But greater average weight loss does not automatically mean better for everyone. The better medication depends on: your diagnosis your weight and health goals your blood sugar status your heart and kidney history your side effect tolerance your contraindications your insurance coverage your ability to sustain treatment your clinicians judgment The goal is not to choose the most aggressive option

Use case: Tendon injuries, muscle tears, joint inflammation, post-surgical recovery